Member Info for WeTookPelham

Bermuda, I was going to ask earlier on here where things stand RE the patent announcement today, and then i noticed you replied to goosed's question over on ADVFN, hope you don't mind but I've taken the liberty of copying it here as im sure it's helpful for others too:

"...goooosed, Intention to grant the enolase patent was originally flagged by Konar and discussed on lse a while ago so not exactly new news. AFAIK the situation with the various Moditope patent applications is as follows:-
1) Original Moditope patent now granted in Europe, US and most major jurisdictions, nb. DNA version split off into new, divisional/continuation applications (see no. 3 below)
2) An additional application was filed by Scancell back in 2016 to cover citrullinated enolase peptides. European Patent Office gave notice of their intention to grant this patent at the end of October, still pending in other jurisdictions. This application is the subject of today's RNS.
3) Two divisional patent applications have been filed with the European Patent Office and one continuation application in the US - these are linked to the original application. They cover the DNA version of Moditope. Also, one of the European divisionals covers a screening process to identify and sort CD4 T cells from patients blood, think this relates to Modi TCR. None of these applications have yet been granted. Shame Konar isn't around, he is the expert!"

Just to add to goosed's question, does this mean the grants should in theory happen now/eventually? I.e. a given? And does it help to cross the t's and dot the i's "if" a potential suitor was thinking "...mmm i like scancell but they better sure have those patents granted before we make an offer!"?

Lol.
https://twitter.com/JIxn123/status/1196140081150644224
Someone has put a nice concise reply to that Dr Ursula thread. Have to say, for the time being, I agree with the sentiment.

...today. Unusually so? What gives?

TF "...I wonder if there'll be any comment on the cooperation with Scancell in this coming update - I'm not holding my breath but you never know :-"

Potential of very last minute RNS just prior to BioNtech update? What odds do we reckon?

HI Bermuda, is it especially significant that it is also on the European Clinical Trials Register now too?

".. scancell (i.e. the BOD) have messed up bigtime on ImmunoBody IMHO... they were slow to get mouse data in CI combo and been very slow to get off the mark for a combo trial..... When you compare to err Oncosec a company whos tech has been over here and been shown as inferior to scancells ImmunoBody well yeah... but look where they are and we are not..."

Well said crumbs...This +1. The BOD have shown awful planning/lack of foresight IMO.

Ah thanks Crumbs, feel free to ignore that post all.
P.S. I've heard of the famous Crumb sized buys...but (tiny) crumb sized sells? ;)

https://patents.google.com/scholar/626801520097166718?q=%22scancell%22&scholar&oq=%22scancell%22&sort=new

Here's the PDF
https://umcure2020-04a2dd4.aldryn-media.com/filer_public/02/4c/024cd021-5f35-45c9-9316-33a3e755f11d/selumetinib.pdf

And from the PDF - "Research funding: Scancell; Non-remunerated activity/ies, PI for clinical trial sponsored
by Scancell: Scancell; Leadership role, Non-remunerated activity/ies, Head of Division of Cancer &
Stem Cells, University of Nottingham: Cancer & Stem Cells, University of Nottingham; Leadership
role"

Hoping the discussion today doesn't go too off topic with Brexit chat, IMO we should be focusing on crumbs email and CH's reply, as it seems to be full of some significant snippets of info.

Ah fair enough, thanks.

Why no RNS(s) about these patent updates?

Well said Crackin, agree wholeheartedly.

@crumbs "...And failure to get this product into a further viable combo trial that could cement its viability as a life-saving treatment... baffling"

Well this (all) lays on the BOD at the end of the day right?

Ah i thought it was only the abstract summary!
https://www.scancell.co.uk/Data/Sites/1/media/publications/papers/brentville-et-al-2019.pdf
...For anyone else who also did not realise the full abstract is there.

Yep definitely one for the science nerds here, any of you care to chime in?

That last line i thought was significant(?) though:
"Immunisation with citrullinated peptides resulted in 90% survival (p < 0.001) against established B16 HHD tumour expressing IFN? inducible DP4. These studies show that citrullinated peptides can be presented by a range of MHC class II molecules, including for the first time HLA-DP4, and are strong targets for anti-tumour immunity"

...if this was already posted? Taken from scientific-papers-posters section of the websites, posted last week:

https://www.scancell.co.uk/t-cell-repertoire-to-citrullinated-self-peptides-in-healthy-humans-is-not-confirmed-to-the-hla-dr-se-alleles-targeting-of-citrullinated-self-peptides-presented-by-hla-dp4-for-tumour-therapy

Balerno, from the RNS:
"As of the date of this announcement, Dr Ursula Ney holds no ordinary shares in the capital of the Company.'

Forgive my ignorance but would she not have been given share options as part of her contract/package instead of buying on the open market?

Actually it's interesting full stop that she holds no shares is it not? Is it because it's her appointment is too close to possible news for that?

Wow...now that's a serious buy. Institutional investors i assume? Will a buy that big require an RNS due it's size/% of shares?

Interesting:

https://www.linkedin.com/in/ursula-ney-7b5a5025?originalSubdomain=uk

"Ursula Ney has more than thirty years of experience in the pharma and biotech industries, with comprehensive knowledge of drug development and partnering. Her experience also includes broad global management, leading integrations and M&A"

Pfft.... People losing patience?